SAT0141 LONG-TERM EFFECTIVENESS OF TOFACITINIB IN CONVENTIONAL DMARDS NON-RESPONDERS WITH RHEUMATOID ARTHRITIS: RESULTS OF RUSSIAN NATIONAL REGISTER
Authors: I. Gaydukova, V. Mazurov, A. Lila, A. Baranov, G. Lukina, E. Zhilyaev, E. Koltsova, E. Shmidt, O. Fomina, I. Bondareva, O. Anoshenkova, A. Vasilenko, E. Vasilenko, N. Yudina, L. Knyazeva, V. Poncratov, E. Gaydukova, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2020)

Background: Tofacitinib is an oral Janus Kinase inhibitor for the treatment of rheumatoid arthritis (RA). Objectives: To evaluate the three-year effectiveness of tofacitinib in RA conventional synthetic (cs) DMARDs non-responders. Methods: Data from 374 patients from Russian national register OREL of patients with RA treated with tofacitinib not less than 3 years after failure of conventional DMARDs were included in the statistical analysis. Clinical and laboratory data from 4 consecutive visits with an interval of 12 months between the visits (± 28 days) were analyzed. Treatment with any biologics ever was an exclusion criteria. Demographical (age, sex) and disease-related characteristics of RA (symptoms duration, RF- and ACCP positivity, presence of joint erosions, DAS28, CDAI, number of tender and swollen joints (NTJ, NSJ), erythrocytes sedimentation rate (ESR), C-reactive protein (CRP)) collected. Statistical analysis performed with statistical programs SPSS2017 and GraphPadPrizm. p-value &lt; 0.05 considered as significant. Results: Baseline characteristics of RA patients, involved in the analysis are presented in table 1. Table 1. Baseline characteristics of the patients with RA (n=374). Parameter Characteristics Male, n (%) 92 (24.5) Age, years (mean±SD) 53.4±13.38 Symptoms duration, month (mean±SD) 140±137 Positive rheumatoid factor (RF), n (%) 123(32.8) Positive antibodies to cyclic citrullinated peptide (ACCP), n (%) 329(87.9) Erosions of hand joints (X-rays), n (%) 372 (99.4) BMI, kg/m 2 (mean ±SD) 26.8 ± 6.14 Smokers (current and in the past), n (%) 54 (14.4) Changes in the diseases activity parameters in patients with RA, treated with tofacitinib not less than 3 years after cs DMARD failure are presented in table 2, figure 1, and figure 2. Figure 1. DAS28 of patients with RA, treated with tofacitinib (n=374) – 3-years follow-up (time-points are presented in years ± 28 days). Figure 2. DAS28 of patients with RA, treated with tofacitinib (n=374) – 3-years follow-up (time-points are presented in years ± 28 days). Table 2. Changes in RA parameters in patients treated with tofacitinib, n=374 (M±SE). Disease characteristics Baseline Year 1 # Year 2 # Year 3 # C-RP, mg/L 30.1±35.0 8.3±12.8 7.6±10.7 9.4±13.5 ESR, mm/h 35.2±21.2 22.7±17.2 21.9±17.7 22.3±17.3 NTJ from 28 11.2±6.5 4.6±4.9 4.8±5.0 3.9±3.8 NTJ from 28 7.6±5.1 2.4±3.2 1.7±3.1 1.4±2.8 *difference with baseline is significant with p&lt;0.000. # - ±28 days Conclusion: According to the real world data treatment with tofacitinib may provide good response rates in RA patients, refractory to the previous csDMARDs treatment in long-term perspective. Acknowledgments : Pfizer Disclosure of Interests: : Inna Gaydukova Grant/research support from: JSC BIOCAD, Speakers bureau: Pfizer, Novartis, AbbVie, JSC BIOCAD, Сelgene, MSD, Sanofi, V Mazurov: None declared, Alexander Lila: None declared, Andrey Baranov Grant/research support from: Bayer, Galina Lukina Speakers bureau: Novartis, Pfizer, UCB, Abbvie, Biocad, MSD, Roche, Evgeniy Zhilyaev Speakers bureau: Novartis, UCB, Pfizer, Biocad, Abbvie, MSD, Roche, Ekaterina Koltsova: None declared, Evgeniya Shmidt Speakers bureau: MSD, Novartis, Pfizer, Oxana Fomina: None declared, Irina Bondareva: None declared, Olga Anoshenkova: None declared, Aleksey Vasilenko: None declared, Elizaveta Vasilenko: None declared, Natalya Yudina: None declared, Larisa Knyazeva: None declared, Vyacheslav Poncratov: None declared, Ekaterina Gaydukova: None declared, Evgeny Nasonov Speakers bureau: Lilly, AbbVie, Pfizer, Biocad, R-Pharm